Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma
US hospitals seeing different kind of COVID surge this time
5 January 2022Nearly 2 million children worldwide develop asthma as a result of breathing in traffic-related pollution
5 January 2022Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile, according to the results of the Phase II/III RELATIVITY-047 clinical trial reported by The University of Texas MD Anderson Cancer Center today in the New England Journal of Medicine.
